Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with -mutated metastatic colorectal cancer: the REVOLUTION study protocol

Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with -mutated metastatic colorectal cancer: the REVOLUTION study protocol

Background: Despite effective treatments, metastatic colorectal cancer (mCRC) prognosis is still poor, mostly in RAS -mutated tumors, thus suggesting the need for novel combinatorial therapies. Epigenetic alterations play an important role in initiation and progression of cancers, including CRC. His...

Full description

Bibliographic Details
Main Authors: Antonio Avallone, Maria Carmela Piccirillo, Elena Di Gennaro, Carmela Romano, Filomena Calabrese, Maria Serena Roca, Fabiana Tatangelo, Vincenza Granata, Antonio Cassata, Ernesta Cavalcanti, Nicola Maurea, Piera Maiolino, Lucrezia Silvestro, Alfonso De Stefano, Francesco Giuliani, Gerardo Rosati, Emiliano Tamburini, Pasquale Aprea, Valeria Vicario, Anna Nappi, Carlo Vitagliano, Rossana Casaretti, Alessandra Leone, Antonella Petrillo, Gerardo Botti, Paolo Delrio, Francesco Izzo, Francesco Perrone, Alfredo Budillon
Format: Article
Language:English
Published: SAGE Publishing 2020-08-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758835920929589

Internet

https://doi.org/10.1177/1758835920929589

Similar Items